StockData
Pelthos Therapeutics Inc. logo

Pelthos Therapeutics Inc. (PTHS) stock

PTHSNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 2/30
$7.10+0.26 (+3.80%)

Close on Nov 18, 2026Market cap $27.18MP/E –Yield –

Pelthos Therapeutics operating cash flow

Operating cash flow is the cash the business generates from its day-to-day operations.

Pelthos Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$42.30M. For fiscal 2025 it was -$22.59M.

Annual operating cash flow

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$22.59M–
FY2024Dec 31, 2024-$5.79M–
FY2023Dec 31, 2023-$981.03K–
FY2022Dec 31, 2022-$1.57M–

Quarterly operating cash flow

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$7.66M–
Q1 FY2026Mar 31, 2026-$13.13M–
Q4 FY2025Dec 31, 2025-$6.25M–
Q3 FY2025Sep 30, 2025-$15.26M–
Q2 FY2025Jun 30, 2025-$447.00K–
Q1 FY2025Mar 31, 2025-$632.00K–
Q4 FY2024Dec 31, 2024-$670.00K–
Q3 FY2024Sep 30, 2024-$177.69K–
Q2 FY2024Jun 30, 2024-$2.95M–
Q1 FY2024Mar 31, 2024-$1.99M–
Q4 FY2023Dec 31, 2023-$356.81K–
Q3 FY2023Sep 30, 2023-$257.24K–
Q2 FY2023Jun 30, 2023-$193.62K–
Q1 FY2023Mar 31, 2023-$173.37K–

More Pelthos Therapeutics figures

See a number that looks wrong?